65239-69-2

Usage

Uses

Used in Organic Synthesis:
2,4-dihydroxy-3-propyl-1',1',1'-trifluoroacetophenone is used as a building block in organic synthesis for its unique structure and functional groups, which facilitate the creation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2,4-dihydroxy-3-propyl-1',1',1'-trifluoroacetophenone is used as an intermediate in the development of various pharmaceuticals due to its enhanced reactivity and selectivity, which are beneficial in the synthesis of new drug candidates.
Used in Agrochemical Production:
2,4-dihydroxy-3-propyl-1',1',1'-trifluoroacetophenone is also utilized in the agrochemical sector as an intermediate for the production of agrochemicals, where its unique properties contribute to the development of effective and targeted products.
Due to its potential applications across various fields, 2,4-dihydroxy-3-propyl-1',1',1'-trifluoroacetophenone is of significant interest to researchers and chemists, who continue to explore its capabilities and applications.

Upstream product

• 353-85-5 trifluoroacetonitrile 
• 13331-19-6 2-propyl-1,3-benzenediol 
• 16929-64-9 1,3-Dimethoxy-2-(prop-1'-yl)benzene 
• 151-10-0 1,3-Dimethoxybenzene 
• 709028-25-1 1-(3-allyl-2,4-dihydroxy-phenyl)-2,2,2-trifluoro-ethanone 
• 407-25-0 trifluoroacetic anhydride 
• 315-44-6 2,4-dihydroxy-1’,1’,1’-trifluoroacetophenone 

Downstream Products

• 118684-12-1 2-tetrahydropyranyl 4-<<4-(trifluoroacetyl)-3-hydroxy-2-propylphenoxy>methyl>benzoate 
• 709028-29-5 (3-Chloro-4-{3-[3-hydroxy-2-propyl-4-(2,2,2-trifluoro-acetyl)-phenoxy]-propylsulfanyl}-phenyl)-acetic acid methyl ester 
• 118683-21-9 4-{[4-(trifluoroacetyl)-3-hydroxy-2-propylphenoxy]methyl}benzoic acid 
• 194608-88-3 7-dipropyl-6-hydroxy-3-trifluoromethyl-1,2-benzisoxazole 
• 709028-30-8 {3-Chloro-4-[3-(3-hydroxy-2-propyl-4-{2,2,2-trifluoro-1-[(Z)-hydroxyimino]-ethyl}-phenoxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 194608-89-4 {3-chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 
• 724471-16-3 2,4-dihydroxy-3-dipropyl-1',1',1'-trifluoroacetophenone oxime 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia

A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2- methylpropionic acid (4) was identified

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Phenylacetic acid derivatives as hPPAR agonists

Beginning with the weakly active lead structure 1, a new series of hPPAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. F

O-Arylmandelic acids as highly selective human PPAR α/γ agonists

A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARα-weighted agonists do not show the typical PPARγ associated side effects of BAT proliferation and cardiac hypertrophy in

Hydroxyacetophenone-derived antagonists of the peptidoleukotrienes

Considerations of the possible similarities between leukotriene D4 and its prototypical antagonist, FPL 55712, led to the development of a new series of leukotriene antagonists incorporating a hydroxyacetophenone group (e.g., the toluic acids 1